spec sheet6 rows
MK-0777 was a Merck compound built to be a benzodiazepine-like drug without the sedation; it selectively potentiated GABA-A receptors carrying the alpha2 or alpha3 subunit instead of hitting alpha1 (the subunit responsible for benzodiazepine sedation and abuse liability). The idea came out of University of Pittsburgh postmortem work showing that GABA neurotransmission onto pyramidal cells in the schizophrenic prefrontal cortex is weakened, which was proposed as a root cause of the working-memory deficits in the disease. A small 2008 open-label-adjacent proof-of-concept trial in chronic schizophrenia patients found real improvements on working-memory tasks and increased frontal gamma power, which made a fair bit of noise in the field. A larger, properly randomized follow-up then failed to replicate the benefit, and Merck quietly let the program lapse; it never advanced past early Phase II.
- improved working memory on N-back and related tasks in an initial small trial
- increased frontal gamma band power during cognitive tasks
- designed to avoid alpha1-mediated sedation seen with classic benzodiazepines
- sedation still reported at some doses
- unclear long-term tolerance profile given GABA-A target
- MK-0777's rationale traced back to postmortem brain tissue studies showing weaker GABA signaling onto prefrontal pyramidal neurons in people who had schizophrenia.
Mechanism
Positive modulator selective for -A receptors containing the alpha2 or alpha3 subunit, sparing the alpha1-containing receptors that drive benzodiazepine sedation and tolerance.
Safetyrisks and cautions, not medical advice
Tolerability was never the problem here. In the 60-patient randomised trial at 3 mg and 8 mg twice daily for four weeks it caused minimal side effects, and the earlier fifteen-patient study said much the same. The uncomfortable finding sits in the efficacy data: patients on placebo scored significantly better than either dose group on visual memory and on reasoning and problem solving, which hints that the drug may have made some cognitive domains slightly worse. Nobody has taken it for longer than a month, and its tolerance and dependence profile at a GABA-A target is unmeasured.
History
Developed by Merck; a 15-subject proof-of-concept trial (Lewis et al, 2008) showed cognitive gains and increased gamma oscillations in schizophrenia patients, but a larger randomized trial failed to confirm efficacy and the compound was shelved around 2010.
Subjective profileweighing the evidence above
A clean mechanistic idea that could not clear the bar of a properly powered trial; the subunit-selective GABA-A hypothesis for schizophrenia cognition mostly died with it.
Resources
This entry is here for reference.
Research
- 1.Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
- 2.A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is MK-0777 available anywhere?
No. It only ever existed as a Merck research compound in clinical trials; it was never sold or manufactured for outside use.
Did MK-0777 actually work for schizophrenia?
A small early trial suggested it helped working memory, but a bigger randomized trial found no significant benefit, which is why Merck stopped developing it.
Limitations of the evidence
- no consistent benefit in the larger confirmatory trial
Adverse effects
- sedation still reported at some doses
- unclear long-term tolerance profile given GABA-A target